Novomics Co (XKRX:283100) Cash-to-Debt : 4.85 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Novomics Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Novomics Co's cash to debt ratio for the quarter that ended in Dec. 2023 was 4.85.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Novomics Co could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Novomics Co's Cash-to-Debt or its related term are showing as below:

XKRX:283100' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.51 Med: 8.15 Max: No Debt
Current: 4.85

During the past 7 years, Novomics Co's highest Cash to Debt Ratio was No Debt. The lowest was 2.51. And the median was 8.15.

XKRX:283100's Cash-to-Debt is ranked worse than
53.96% of 1527 companies
in the Biotechnology industry
Industry Median: 6.23 vs XKRX:283100: 4.85

Novomics Co Cash-to-Debt Historical Data

The historical data trend for Novomics Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Novomics Co Cash-to-Debt Chart

Novomics Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

19.68

8.15

7.02

2.51

4.85

Novomics Co Semi-Annual Data
	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Cash-to-Debt	Get a 7-Day Free Trial			19.68	8.15	7.02	2.51	4.85

Competitive Comparison of Novomics Co's Cash-to-Debt

For the Biotechnology subindustry, Novomics Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novomics Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novomics Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Novomics Co's Cash-to-Debt falls into.

Novomics Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Novomics Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1988.706	/	(299.136	+	110.79)
	=	4.85

Novomics Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1988.706	/	(299.136	+	110.79)
	=	4.85

Novomics Co (XKRX:283100) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Novomics Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Novomics Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Novomics Co (XKRX:283100) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novomics Co Ltd (XKRX:283100) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

171 Dangsan-ro, 304, 305, 306, 306-1, Yeongdeungpo-gu, Seoul, KOR

Website

http://www.novomics.com

Novomics Co Ltd is a developer of a molecular diagnosis system for cancer treatment.

Novomics Co (XKRX:283100) Headlines

No Headlines